Health Canada Approves Novavax Vaccine For COVID-19 

Health Canada has approved Novavax’s adapted COVID-19 vaccine, Nuvaxovid XBB.1.5, targeting individuals aged 12 and above. CBC News report.

The vaccine, also authorized as a booster for those 18 and older, utilizes a traditional approach to enhance immunity against severe infection and related complications. 

Novavax anticipates widespread availability of doses in Canada. The company’s initial COVID-19 vaccine, Nuvaxovid, received approval for individuals aged 18 and over in February 2022. Pfizer-BioNTech and Moderna have also updated their mRNA vaccines to address the XBB.1.5 variant, with approval for use in Canada, including children under 12. 

Novavax’s vaccine employs lab-grown spike protein copies to stimulate an immune response, a technique used in certain flu and hepatitis B vaccines. Canada’s advisory committee generally recommends waiting approximately six months post-vaccination or infection before receiving the latest COVID-19 vaccine.

The approval aligns with the ongoing COVID-19 hospitalizations, with about 4,600 beds occupied across the country, reminiscent of levels in January. As the annual influenza season commences, health officials urge Canadians to get vaccinated against the flu and respiratory syncytial virus to safeguard against potential peaks during the holiday season.

Read also:

SHOCK: Health Canada Confirms a Virus in the Pfizer COVID-19 Vaccine, Undisclosed By the Manufacturer 

Alberta Resolves To Prevent Future Vaccine Mandate in Opposition to Bill C-278 

Critics To Take a U-Turn as New Evidence Confirms The Overwhelming Safety of COVID-19 Vaccines 

0 Replies
Inline Feedbacks
View all replies